MK-0686

DB12563InvestigationalSmall molecule

MK0686 has been used in trials studying the treatment of Osteoarthritis, Pain, Postoperative, and Neuralgia, Postherpetic.

Mechanism: Pharmacologically active on B1 bradykinin receptor
Curator reviewed
Formula / weight: C₂₂H₁₉ClF₄N₂O₄ · 486.85 g/mol (avg)
Code names: MK0686

Resolves to

Compound

Structure

InChIKeyWZZIQHIQMWJNLU-LLVKDONJSA-NSMILESCOC(=O)C1=C(Cl)C=CC=C1C1=CC=C([C@@H](C)NC(=O)C2(CC2)NC(=O)C(F)(F)F)C(F)=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0686, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.